Introduction {#s1}
============

Diffuse congenital hyperinsulinism in infancy (CHI-D) affects the entire pancreas and is characterized by persistent, inappropriate release of insulin in the presence of low blood glucose, commonly accompanied by macrosomia, indicating altered intrauterine development ([@B1],[@B2]). Inactivating mutations in either the *ABCC8* or *KCNJ11* genes, which encode subunits of the K~ATP~ channel, account for approximately 90% of those cases ([@B3],[@B4]) where hypoglycemia necessitates partial or near-total pancreatectomy ([@B1],[@B2]). These mutations cause persistent β-cell depolarization, inappropriate calcium entry, and insulin secretion ([@B5]).

Two features of CHI-D imply more diverse pathophysiology. First, some reports have shown increased rates of β-cell proliferation by Ki67, which detects all stages of the cell-cycle except G~0~ ([@B6]--[@B8]). Understanding how CHI-D might promote human β-cell replication is desirable for therapeutic exploitation in diabetes. While the glucose-sensing/insulin secretion pathway can regulate β-cell proliferation ([@B9]) and an intricate array of cell cycle proteins is in place ([@B10]), normal human β-cells are recalcitrant in proliferation assays compared with their rodent counterparts ([@B11]). Second, alterations outside the β-cell lineage imply consequences from abnormal β-cells or that CHI-D directly affects other pancreatic lineages. For instance, pancreatic polypeptide (PP) cells and somatostatin-stained δ-cells have been reported as altered in CHI-D ([@B12]). Certainly, K~ATP~ channels are expressed in other islet cell types, and normal β-cell function relies on multiple intraislet interactions ([@B5]).

In this study we explored potential defects in differentiation, maturity, and proliferation of β-cells and other pancreatic lineages in CHI-D caused by mutant K~ATP~ channels.

Research Design and Methods {#s2}
===========================

Human Tissue {#s3}
------------

Following ethical approval, national codes of practice, and informed consent, pancreatic tissue was received from 10 cases of CHI-D ([Supplementary Table 1](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db14-1202/-/DC1)) or normal control samples as previously described ([@B13]). CHI-D was diagnosed from established clinical and histopathological criteria ([@B1],[@B2]) and the identification of *ABCC8* or *KCNJ11* mutations ([Supplementary Table 1](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db14-1202/-/DC1)). Postnatal control cases (2 days to 36 months \[*n* = 16\] or ≥12 years old \[*n* = 4\]) died of nonpancreatic diagnoses and showed unremarkable pancreatic histology. Fetal control material (*n* = 4) was obtained and processed 10 to 35 weeks post-conception (wpc) as described previously ([@B14],[@B15]).

Immunohistochemistry, Immunofluorescence, and Cell Counting {#s4}
-----------------------------------------------------------

Immunohistochemistry and immunofluorescence were performed as described previously ([@B14],[@B15]) ([Supplementary Table 2](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db14-1202/-/DC1)). High-content assessment of Ki67^+^ cells and insulin^+^ surface area followed digitization of slides (3D Histech Pannoramic 250 Flash II) using Pannoramic Viewer and HistoQuant software. At least 20 regions of interest were selected (free from connective tissue), and Ki67^+^ cells were calculated as a fraction of the total cell count. No regional differences were measured. Dual staining of Ki67 and pancreatic lineage markers was assessed from 10 randomly selected fields of view at ×200 magnification in at least two positions within each CHI-D or control pancreas or in the entire section (fetal samples; those of smaller size). Apoptosis combined immunofluorescence for insulin using a conjugated Alexa-Fluor dye (Life Technologies, Paisley, U.K.) with fluorescein isothiocyanate--labeled terminal deoxynucleotidyl TUNEL according to the manufacturer's instructions (Trevigen, Gaithersburg, MD). DNase I treatment and omission of the terminal transferase enzyme served as positive and negative controls, respectively.

Isolation of RNA, RT-PCR, and Quantitative PCR {#s5}
----------------------------------------------

Total RNA was isolated from whole tissue sections using the Qiagen RNeasy FFPE kit protocol according to the manufacturer's instructions. Quantitative RT-PCR was performed as described previously, using the ΔΔCT method standardized to *HPRT* and *β-ACTIN* and compared with age-matched controls ([@B16],[@B17]) (primers in [Supplementary Table 3](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db14-1202/-/DC1)).

Statistical Analysis {#s6}
--------------------

Cell counting data are presented as mean ± standard error. Patient and control samples were compared using the Mann-Whitney *U* test and correlation was assessed using the Spearman rank correlation test.

Results {#s7}
=======

Islet Structure and Hormone Colocalization in CHI-D {#s8}
---------------------------------------------------

CHI-D α-cells and δ-cells were more diffusely scattered throughout the islet compared with a peripheral mantle location in early postnatal control tissue ([Supplementary Figs. 1*A--D* and 2*A--D*](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db14-1202/-/DC1)). This tended to resolve to matched control tissue by the end of the first year; however, the overall islet structure remained less organized and compact in CHI-D ([Supplementary Figs. 1*E--F* and 2*E--F*](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db14-1202/-/DC1)). In two of the CHI-D samples from early infancy 2--5% of glucagon-positive and insulin-positive cells contained both hormones, similar to fetal pancreas but not observed in any of the postnatal control samples ([Supplementary Fig. 3](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db14-1202/-/DC1) and [Supplementary Video](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db14-1202/-/DC1)). Colocalization was not observed for insulin with somatostatin, ghrelin, or PP.

"Fetal-Like" NKX2.2 in Early Postnatal CHI-D δ-Cells {#s9}
----------------------------------------------------

Given this potential immaturity, we looked for signs of endocrine differentiation in CHI-D. *NEUROG3* detection from whole tissue sections was no higher in CHI-D than age-matched controls and much lower than when fetal NEUROG3-positive cells are most abundant ([@B13]) ([Fig. 1*A*](#F1){ref-type="fig"}). We did not detect convincing NEUROG3 immunoreactivity in CHI-D or age-matched controls spanning the first year after birth (data not shown). FOXA2 (in β-cells and duct cells), NKX6.1 (β-cells), SOX9 (duct cells), and GATA4 (acinar cells) were all appropriately detected as nuclear proteins in their respective cell types in CHI-D and age-matched controls ([Supplementary Fig. 4](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db14-1202/-/DC1); data not shown). Mean expression of *INSULIN*, *PDX1*, *FOXA2*, *SOX9*, *NKX6.1*, *MAFA*, and *MAFB* from whole tissue sections was not altered in CHI-D samples ([Fig. 1*B*](#F1){ref-type="fig"}). While *NKX2.2* was increased before Hochberg correction, *PAX4* and *ARX* were consistently decreased statistically (control levels of *NKX2.2* were constant during the first year; [Fig. 1*B*](#F1){ref-type="fig"}). This trend toward increased *NKX2.2* in CHI-D reflected cases up to 6 months of age ([Fig. 1*C*](#F1){ref-type="fig"}). Nuclear NKX2.2 protein was detected by immunofluorescence in virtually all β-cells, 80--90% of α-cells, and 75--90% of ghrelin-positive cells in CHI-D, fetal, and postnatal control samples. By contrast, NKX2.2 was detected in two-thirds of CHI-D and fetal δ-cells but only in 25% of age-matched control cells ([Fig. 1*D* and *E*](#F1){ref-type="fig"}). Given this alteration, we examined nucleomegaly, another feature of CHI-D ([@B8],[@B16]). CHI-D islet cells tended to have a slightly larger nucleus than age-matched controls, with a clear subset outside a normal distribution showing a \>50% increase in nuclear diameter ([Supplementary Fig. 5*A*](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db14-1202/-/DC1)). Most of the cells with these enlarged nuclei stained for insulin and β-cell transcription factors including NKX6.1 and ISL1 (PDX1 was missing occasionally; [Supplementary Fig. 5*B*](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db14-1202/-/DC1)). Nucleomegaly was not observed in CHI-D cells positive for glucagon, PP, or ghrelin or in duct or acinar cells (data not shown; [Supplementary Fig. 4*A* and *G*](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db14-1202/-/DC1)). However, 10% of nucleomegalic cells contained somatostatin, implying a δ-cell identity ([Supplementary Fig. 5*C*](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db14-1202/-/DC1)).

![Expression of key transcription factors in CHI-D pancreas. *A*: Quantitative RT-PCR analysis of *NEUROG3* in triplicate in CHI-D1 and CHI-D2 and age-matched controls (mean ± SEM) standardized against levels of detection in the human fetal pancreas at 14 wpc. Co, control; mo, months. *B*: Quantitative RT-PCR analysis of 11 transcription factors and insulin. Data from each CHI-D sample were analyzed in triplicate and standardized against their own age-matched control before displaying data as means ± SEM for all CHI-D samples. \**P* \< 0.01 following Hochberg correction. *C*: Quantitative RT-PCR expression of *NKX2.2* in CHI-D samples (performed in triplicate; mean ± SEM) during the first 6 months compared with their age-matched controls. *D*: Cell counting of dual immunofluorescence for NKX2.2 with islet hormones, insulin (INS), glucagon (GLU), somatostatin (SS), and ghrelin (GHREL) for the four CHI-D samples in *C*, their age-matched controls, and human fetal pancreas (two specimens at 11 and 15 wpc). Data are expressed as the mean percentage ± SEM for each hormone lineage. NKX2.2 is retained in somatostatin-positive CHI-D cells compared with age-matched controls (\**P* \< 0.01). *E*: Examples (as counted in *C*) of dual immunofluorescence for SS and NKX2.2 counterstained with DAPI. Arrows show colocalization in fetal and CHI-D samples. Scale bar = 10 µm.](db141202f1){#F1}

Increased Cell Proliferation in CHI-D Occurs Mostly in Exocrine Cells {#s10}
---------------------------------------------------------------------

Recognizing that CHI-D extended beyond β-cells, we studied proliferation in different pancreatic lineages. Total proliferation in control pancreas declined between 10 wpc and 36 months of age ([Fig. 2*A*](#F2){ref-type="fig"}), with a very low rate from 12 years onward. During months 1--13, Ki67 count was increased in every CHI-D case compared with age-matched controls ([Fig. 2*B*](#F2){ref-type="fig"}). This increased Ki67 count was particularly noticeable after the first 4 months, consistent with maintained proliferation in CHI-D, when replication in normal pancreas was declining. The declining proliferation in normal pancreas during the first year was largely in acinar cells ([Fig. 3*A* and *B*](#F3){ref-type="fig"}). Very little proliferation in α-cells and β-cells was detected beyond 1 year of age. Only two of five cases studied (CHI-D 1 and CHI-D 9) showed elevated β-cell proliferation compared with their controls, the same proportion of specimens with increased α-cell proliferation (CHI-D 1 and CHI-D 2) ([Fig. 3*C*](#F3){ref-type="fig"}). By contrast, four of the five cases showed increased duct cell proliferation (5- to 11-fold), whereas all five cases demonstrated increased acinar cell proliferation, which was progressively more noticeable with age. Apoptosis by TUNEL seemed negligible in exocrine tissue and α-cells. As found by Kassem et al. ([@B6]), apoptosis in β-cells was increased ([Fig. 3*D*](#F3){ref-type="fig"}), raising the question of whether Ki67 truly reflected cell proliferation or, potentially, DNA damage with attempted repair. As an additional marker of proliferation analyzed in \>100,000 cells, we found phosphohistone H3--positive cells were, on average, fivefold more prevalent in CHI-D (*n* = 2 cases) than in age-matched controls (*n* = 2 cases) and were most prevalent in acinar cells ([Supplementary Fig. 6](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db14-1202/-/DC1)), similar to the data on Ki67 ([Fig. 2*B*](#F2){ref-type="fig"}\[i\]). Also, we found no evidence of colocalization of phospho-γ-H2AX (a marker of DNA damage) with Ki67-positive cells. Furthermore, *INSULIN* expression was equivalent between CHI-D and controls ([Fig. 1*B*](#F1){ref-type="fig"}), and the surface area of insulin staining was statistically unchanged between CHI-D (4.9 ± 0.37% \[mean ± SEM\] of sections; 2--13 months; *n* = 5) and age-matched controls (5.8 ± 0.38%; 1--10 months; *n* = 4). These multiple strands of evidence imply no increase of β-cell mass in CHI-D but predominant proliferation in exocrine cells.

![Cell proliferation is increased in CHI-D tissue. *A*: Proliferation in human control pancreas from 10 wpc, during the first year after birth (weeks, months), and ≥12 years (yr). All data points were gathered from individual cases, except for the data associated with ≥12 years, which are averaged from four cases. Proliferation was assessed by high-density counting from a minimum of 20,000 cells, with Ki67^+^ cells expressed as a percentage of the total cell count. *Ai*--*iv*: Representative images from fetal tissue at 18 wpc and postnatal pancreas at 10 weeks and 10 months. Ki67^+^ cells are stained brown and are clearly seen in islets (arrows in panel *Aiv*). Scale bars represent 100 μm in *Ai--iii* and 50 μm in *Aiv*. *B*: Proliferation in CHI-D tissue. *Bi*: Average fold increase in Ki67 count expressed relative to age-matched controls from cases up to 4 months and the older ones. *Bii*: Individual data from the nine cases compared with age-matched controls demonstrate particularly higher proliferation rates at older ages. C, age-matched control; mo, months; \#, patient identifier.](db141202f2){#F2}

![Increased proliferation in all pancreatic cell lineages in CHI-D tissue. *A*: Dual immunofluorescence of markers for endocrine cells (β-cells, insulin; α-cells, glucagon) and nonendocrine cells (duct cells, SOX9; acinar cells, GATA4) (green) in the pancreas with Ki67 (red) for CHI-D pancreas, postnatal control tissue, and an example of fetal tissue at 14 wpc. Arrows show examples of costained cells. Scale bar = 20 μm in all panels. *B*: Total counts (±SEM) for Ki67^+^ cells dual-stained for the markers of different pancreatic lineages in human control pancreas. Total Ki67 count was correlated inversely with age (*r*^2^ = −0.929; *P* \< 0.01). w, weeks; yr, years. *C*: Fold increase (±SEM) in proliferation for each cell lineage (as defined by the markers in *A*) for each CHI-D sample compared with its age-matched control (C). Each bar stacks the fold increments for each cell lineage. mo, months. *D*: Relative counts (±SEM) for TUNEL-positive/insulin-positive cells expressed as a percentage of the total insulin-positive cells for fetal and CHI-D samples and their age-matched postnatal controls. Statistical analysis performed using Mann-Whitney *U* test. \**P* \< 0.05, \*\**P* \< 0.01.](db141202f3){#F3}

Nuclear CDK6 and P27 in CHI-D {#s11}
-----------------------------

G~1~/S cell cycle molecules (e.g., CDK6) tend to be cytoplasmic in adult human β-cells ([@B17]--[@B19]), but upon forced nuclear translocation, they can drive proliferation ([@B17],[@B18]). CDK6 staining was predominantly cytoplasmic in control β-cells at 2--3 months, with occasional cells including nuclear localization ([Fig. 4*A*](#F4){ref-type="fig"}, arrowhead). Staining in fetal β-cells was similarly cytoplasmic at 15 wpc ([Fig. 4*B*](#F4){ref-type="fig"}). By contrast, cytoplasmic CDK6 was less noticeable in CHI-D β-cells but clearly nuclear in a proportion ([Fig. 4*C* and *D*](#F4){ref-type="fig"}). CDK6 was also nuclear in many CHI-D CK19-positive duct cells ([Fig. 4*D*](#F4){ref-type="fig"}) and acinar cells ([Fig. 4*C*](#F4){ref-type="fig"}).

![Increased nuclear localization of CDK6 and P27 in CHI-D. Bright-field immunohistochemistry counterstained with toluidine blue and dual immunofluorescence counterstained with DAPI for CDK6 (*A--D*) or P27 (*F--I*) in postnatal control pancreas, samples of fetal pancreas, and CHI-D. Costaining is with insulin except for samples with CK19 in *D* and *I*. Hatched lines in the bright-field images encircle islets. *A--D*: Arrowhead in the merged panel of *A* points to insulin-positive cells, in which CDK6 localizes to both cytoplasm and nucleus. In *C*, the cytoplasmic CDK6 is very much reduced in CHI-D compared with control (Cont) or fetal β-cells, whereas the arrow in the merged panel (and arrows in *D*) points to clear nuclear CDK6 in insulin-positive cells. *E*: Quantitative RT-PCR showing increased *CDKN1B* expression in CHI-D (mean ± SE from five cases across the first 13 months of age) compared with age-matched controls (*n* = 3). \**P* \< 0.05, Mann-Whitney *U* test. *F--I*: P27 is almost exclusively cytoplasmic in postnatal control β-cells, whereas it is almost exclusively nuclear in fetal and CHI-D β-cells and in CK-19-positive duct cells. Scale bars = 50 µm (*A* and *C)*, 20 µm (*B*), and 10 µm (*D* and *F--I*). mo, months.](db141202f4){#F4}

Based on these findings, we generated an interactome model of network clusters derived from a CHI microarray data set ([@B20]) ([Supplementary Fig. 7*A*](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db14-1202/-/DC1)). A total of 1,288 genes were significantly altered (*P* \< 0.05, ANOVA), which yielded 140 functional modules. When the gene most centrally associated with each module ([Supplementary Fig. 7*B*](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db14-1202/-/DC1)) was ranked by its priority score as an index of centrality, the module containing *CDKN1B* came third ([Supplementary Table 4](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db14-1202/-/DC1)). *CDKN1B* encodes P27, which can potentially inhibit proliferation or act as a chaperone for entry of the CDK6--cyclin complex into the nucleus ([@B17]--[@B19]). *CDKN1B* expression was increased almost eightfold in CHI-D pancreas relative to that of the age-matched control ([Fig. 4*E*](#F4){ref-type="fig"}). P27 was almost entirely cytoplasmic in postnatal control β-cells but extensively nuclear in CHI-D and fetal β-cells ([Fig. 4*F--H*](#F4){ref-type="fig"}). P27 also was nuclear in CHI-D duct and acinar cells ([Fig. 4*I*](#F4){ref-type="fig"}; data not shown). Not all cells with these altered cell cycle proteins were nucleomegalic ([Supplementary Fig. 8](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db14-1202/-/DC1)).

Discussion {#s12}
==========

Studying the histopathology of CHI-D cases is useful because modeling in mice with mutant *Abcc8* and *Kcnj11* has failed to phenocopy all aspects of the disorder. Here, islet disorganization in CHI-D was consistent with findings in *Abcc8* and *Kcnj11* mutant mice ([@B21],[@B22]). While we did not observe increased PP cells ([@B12]), developmental transcription factors were altered. NKX2.2 helps maintain β-cell identity ([@B23]), and mutations cause neonatal diabetes ([@B24]). The tendency toward increased *NKX2.2* in CHI-D pancreas concurs with low *ARX* expression, which it represses ([@B23]), and is consistent with an unexpanded PP cell population. Although CHI-D δ-cells were sparse ([@B12]), they more frequently contained NKX2.2, like fetal δ-cells, and made up 10% of endocrine cells with nucleomegaly. It is difficult to conceive that these two δ-cell alterations are secondary to inappropriate insulin from β-cells, arguing that CHI-D directly affects multiple endocrine lineages in keeping with expression of the K~ATP~ channel subunits in multiple islet cell types in mice ([@B22]). Atypical nuclei in β-cells and δ-cells might raise concern over future tumor risk; however, CHI-D is not known to predispose to islet cell tumors. Nevertheless, potential δ-cell immaturity tallies with clinical use of somatostatin analogs to inhibit insulin release in CHI-D ([@B1]), reviving the notion that the disorder could be in part a defect of δ-cells ([@B12]). By contrast, acinar and duct cells are not known to contain the K~ATP~ channel. Their augmented proliferation might therefore reflect inappropriate local insulin concentrations.

Understanding how human β-cells might be provoked into proliferation is a major therapeutic target in diabetes. CHI-D provides a distinctive opportunity to characterize β-cell proliferation in native human tissue. Our data on CDK6 intracellular localization add new weight to the model that its nuclear exclusion is a major checkpoint for human β-cell replication ([@B10]) and support P27 as its potential nuclear chaperone rather than a cell cycle inhibitor ([@B18]).

In summary, we report altered pancreatic transcription factors and cell cycle proteins in CHI-D. How these features relate to the loss of functional K~ATP~ channels, hypoglycemia, and inappropriate insulin release would now be interesting to investigate and could assist in the longer-term care of patients with CHI-D.

Supplementary Material
======================

###### Supplementary Data

This article contains Supplementary Material online at <http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db14-1202/-/DC1>.
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